57148-35-3

Upstream product

• 14504-07-5 2-acetoxy-4-methylbenzoic acid 
• 10026-13-8 phosphorus pentachloride 
• 50-85-1 2-hydroxy-p-toluic acid 

Downstream Products

• 92397-17-6 (E)-2-(2-Acetoxy-4-methyl-benzoyl)-3-hydroxy-but-2-enoic acid ethyl ester 
• 49667-22-3 2-hydroxy-4-methylbenzamide 
• 141-78-6 ethyl acetate 
• 92397-12-1 ethyl 2,7-dimethyl-4-oxo-4H-chromene-3-carboxylate 
• 55411-40-0 3',5'-dichloro-2,4'-dihydroxy-4-methyl-benzanilide 
• 1237514-75-8 2-(2-hydroxy-4-methylbenzamido)-4-phenylbenzoic acid 
• 1237519-25-3 methyl 2-(2-acetoxy-4-methylbenzamido)-4-phenylbenzoate 
• 1375074-75-1 4-imino-8-methyl-3-phenyl-2-thioxo-1,2,3,4-tetrahydro-5H-chromeno[2,3-d]pyrimidine-5-one 

Relevant academic research and scientific papers

Novel quinolizidine salicylamide influenza fusion inhibitors

A novel series of quinolizidine salicylamides was synthesized as specific inhibitors of the H1 subtype of influenza A viruses. These inhibitors inhibit the pH-induced fusion process, thereby blocking viral entry into host cells. Compound 16 was the most active inhibitor in this series with an EC50 of 0.25 μg/mL in plaque reduction assay. The synthesis and the SAR of these compounds are discussed.

Synthesis and antioxidant activities of berberine 9-: O -benzoic acid derivatives

Although berberine (BBR) shows antioxidant activity, its activity is limited. We synthesized 9-O-benzoic acid berberine derivatives, and their antioxidant activities were screened via ABTS, DPPH, HOSC and FRAP assays. The para-position was modified with halogen elements on the benzoic acid ring, which led to an enhanced antioxidant activity and the substituent on the ortho-position was found to be better than the meta-position. Compounds 8p, 8c, 8d, 8i, 8j, 8l, and especially 8p showed significantly higher antioxidant activities, which could be attributed to the electronic donating groups. All the berberine derivatives possessed proper lipophilicities. In conclusion, compound 8p is a promising antioxidant candidate with remarkable elevated antioxidant activity and moderate lipophilicity.

N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF

An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or the like; R2 represents a hydrogen atom or the like; R3 represents an optionally substituted aryl group or the like; X1 represents a carbonyl group; X2 represents a bonding hand; X3 represents a bonding hand; X4 represents a bonding hand or the like; and A represents an optionally substituted phenyl group or the like.)

N-ACYL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF

An N-acyl anthranilic acid derivative represented by general formula (1) or a salt thereof is useful for prevention or treatment of diseases associated with excessive production of collagen. (In the formula, R1 represents a carboxyl group or th

Synthesis of novel thiopyrimidines: An investigation of anti-tubercular and antimicrobial activity

A variety of novel sulfur-containing tricyclic pyrimidine derivatives have been synthesized via the reaction of 2-amino-4-oxo-4H-chromene-3-carbonitriles 3(a-f) with different reagents and characterized by IR, 1H NMR, 13C NMR, mass spectrometry and elemen

4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described.

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).

Treatment of elevated histamine and uric acid levels

Compounds having the general formula SPC1 (the meanings of R1, R2, R3, R4 and R5 are indicated hereinafter) and the pharmaceutically acceptable salts and esters thereof exhibit strong activities in inhibiting histidine decarboxylase and xanthine oxidase. One example is the compound of the formula SPC2